Visfatin, glucose metabolism and vascular disease: A review of evidence

Diabetology and Metabolic Syndrome

Volumn 2, Issue 1, 2010, Pages

  Saddi Rosa, Pedro ^a   Oliveira, Carolina Sv ^a   Giuffrida, Fernando Ma ^a,b   Reis, André F ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF BAHIA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTINEOPLASTIC AGENT; APOLIPOPROTEIN B; C REACTIVE PROTEIN; FIBRINOGEN; GLUCOSE; HEMOGLOBIN A1C; HEPATOCYTE NUCLEAR FACTOR 1BETA; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; N [4 (1 BENZOYL 4 PIPERIDINYL)BUTYL] 3 (3 PYRIDINYL)ACRYLAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OXIDIZED LOW DENSITY LIPOPROTEIN; PIOGLITAZONE; ROSIGLITAZONE;

ACUTE CORONARY SYNDROME; ADIPOCYTE; ADIPOSE TISSUE; APOPTOSIS; ATHEROSCLEROSIS; BARIATRIC SURGERY; BIOSYNTHESIS; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ENDARTERECTOMY; CELL FUNCTION; CHROMOSOME 7Q; CORONARY ARTERY DISEASE; CREATININE CLEARANCE; CYTOKINE RELEASE; EXON; FATTY LIVER; FIBRINOGEN BLOOD LEVEL; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC VARIABILITY; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HEART PROTECTION; HEMOGLOBIN BLOOD LEVEL; HETEROZYGOSITY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INTRAABDOMINAL FAT; INTRON; LIPID METABOLISM; MACROPHAGE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STABLE ANGINA PECTORIS; SUBCUTANEOUS FAT; UNSTABLE ANGINA PECTORIS; URINARY EXCRETION; VASCULAR DISEASE;

EID: 77953391106     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/1758-5996-2-21     Document Type: Review

References (43)

1. Adiponectin: A novel adipokine linking adipocytes and vascular function. BJ Goldstein R Scalia, J Clin Endocrinol Metab 2004 89 6 2563 2568 10.1210/jc.2004-0518 15181024 (Pubitemid 38766332)
2. A review of the cost of cardiovascular disease. JE Tarride M Lim M DesMeules W Luo N Burke D O'Reilly J Bowen R Goeree, Can J Cardiol 2009 25 6 195 202 19536390
3. The new adipose tissue and adipocytokines. C Bulcao SR Ferreira FM Giuffrida FF Ribeiro-Filho, Curr Diabetes Rev 2006 2 1 19 28 10.2174/157339906775473617 18220614 (Pubitemid 44096614)
4. Cytokines, endothelial dysfunction, and insulin resistance. MH de Carvalho AL Colaco ZB Fortes, Arq Bras Endocrinol Metabol 2006 50 2 304 312 16767296 (Pubitemid 43799115)
5. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. A Fukuhara M Matsuda M Nishizawa K Segawa M Tanaka K Kishimoto Y Matsuki M Murakami T Ichisaka H Murakami et al. Science 2005 307 5708 426 430 10.1126/science.1097243 15604363 (Pubitemid 40139988)
6. Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is constitutively released from human hepatocytes. A Garten S Petzold A Barnikol-Oettler A Körner WE Thasler J Kratzsch W Kiess R Gebhardt, Biochem Biophys Res Commun 2010 391 1 376 81 10.1016/j.bbrc.2009.11.066 19912992
7. Skeletal Muscle NAMPT is Induced by Exercise in Humans. SR Costford S Bajpeyi M Pasarica DC Albarado SC Thomas H Xie T Church SA Jubrias KE Conley SR Smith, Am J Physiol Endocrinol Metab 2010 98 117 E126 10.1152/ajpendo.00318.2009
8. Is visfatin an adipokine or myokine? Evidence for greater visfatin expression in skeletal muscle than visceral fat in chickens. SM Krzysik-Walker OM Ocán-Grove SR Maddineni GL Hendricks R Ramachandran, Endocrinology 2008 149 4 1543 50 10.1210/en.2007-1301 18096661 (Pubitemid 351468312)
9. Autocrine effects of visfatin on hepatocyte sensitivity to insulin action. V Skop K Kontrov V Zídek J Sajdok M Pravenec L Kazdov K Mikulík J Zídkov Physiol Res 2009 19929131
10. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. JR Revollo A Korner KF Mills A Satoh T Wang A Garten B Dasgupta Y Sasaki C Wolberger RR Townsend et al. Cell Metab 2007 6 5 363 375 10.1016/j.cmet.2007.09.003 17983582 (Pubitemid 350011996)
11. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. CA Curat V Wegner C Sengenès A Miranville C Tonus R Busse, Diabetologia 2006 49 744 7 10.1007/s00125-006-0173-z 16496121 (Pubitemid 43357549)
12. Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation. V Varma A Yao-Borengasser N Rasouli AM Bodles B Phanavanh MJ Lee T Starks LM Kern HJ Spencer RE McGehee Jr SK Fried PA Kern, J Clin Endocrinol Metab 2007 92 666 672 10.1210/jc.2006-1303 17090638 (Pubitemid 46255312)
13. Retraction. A Fukuhara M Matsuda M Nishizawa K Segawa M Tanaka K Kishimoto Y Matsuki M Murakami T Ichisaka H Murakami E Watanabe T Takagi M Akiyoshi T Ohtsubo S Kihara S Yamashita M Makishima T Fuanahashi S Yamanaka R Hiramatsu Y Matsuzawa I Shimomura, Science 2007 318 5850 565 10.1126/science.318.5850.565b 17962537
14. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. SH Jia Y Li J Parodo A Kapus L Fan OD Rotstein JC Marshall, J Clin Invest 2004 113 9 1318 27 15124023 (Pubitemid 39069931)
15. Pre-B-cell colony-enhancing factor as a potential novel biomarker in acute lung injury. SQ Ye BA Simon JP Maloney A Zambelli-Weiner L Gao A Grant RB Easley BJ McVerry RM Tuder T Standiford et al. Am J Respir Crit Care Med 2005 171 4 361 370 10.1164/rccm.200404-563OC 15579727 (Pubitemid 40223404)
16. Adipokines and cytokines in non-alcoholic fatty liver disease. MH Jarrar A Baranova R Collantes B Ranard M Stepanova C Bennett Y Fang H Elariny Z Goodman V Chandhoke et al. Aliment Pharmacol Ther 2008 27 5 412 421 18081738
17. Influence of visfatin on histopathological changes of non-alcoholic fatty liver disease. R Aller DA de Luis O Izaola MG Sagrado R Conde MC Velasco T Alvarez D Pacheco JM Gonzalez, Dig Dis Sci 2009 54 8 1772 1777 10.1007/s10620-008-0539-9 19005759
18. Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus. K Takebayashi M Suetsugu S Wakabayashi Y Aso T Inukai, Metabolism 2007 56 4 451 458 10.1016/j.metabol.2006.12.001 17378999 (Pubitemid 46427838)
19. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. M Hasmann I Schemainda, Cancer Res 2003 63 21 7436 7442 14612543 (Pubitemid 37413486)
20. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. J Berndt N Kloting S Kralisch P Kovacs M Fasshauer MR Schon M Stumvoll M Bluher, Diabetes 2005 54 10 2911 2916 10.2337/diabetes.54.10.2911 16186392 (Pubitemid 41401086)
21. The relationship of visfatin/pre-B-cell colony-enhancing factor/nicotinamide phosphoribosyltransferase in adipose tissue with inflammation, insulin resistance, and plasma lipids. Y Chang T Chang W Lee L Chuang, Metab Clin Exp 2010 59 1 93 9 19765775
22. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. DG Haider K Schindler G Schaller G Prager M Wolzt B Ludvik, J Clin Endocrinol Metab 2006 91 4 1578 1581 10.1210/jc.2005-2248 16449335
23. Serum visfatin increases with progressive beta-cell deterioration. A Lopez-Bermejo B Chico-Julia M Fernandez-Balsells M Recasens E Esteve R Casamitjana W Ricart JM Fernandez-Real, Diabetes 2006 55 10 2871 2875 10.2337/db06-0259 17003355 (Pubitemid 44923689)
24. The release of the adipocytokine visfatin is regulated by glucose and insulin. DG Haider G Schaller S Kapiotis C Maier A Luger M Wolzt, Diabetologia 2006 49 8 1909 1914 10.1007/s00125-006-0303-7 16736128 (Pubitemid 44025046)
25. Visfatin regulates insulin secretion, insulin receptor signalling and mRNA expression of diabetes-related genes in mouse pancreatic beta-cells. JE Brown DJ Onyango M Ramanjaneya AC Conner ST Patel SJ Dunmore HS Randeva, J Mol Endocrinol 2010 44 3 171 8 10.1677/JME-09-0071 19906834
26. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. MP Chen FM Chung DM Chang JC Tsai HF Huang SJ Shin YJ Lee, J Clin Endocrinol Metab 2006 91 1 295 9 10.1210/jc.2005-1475 16234302
27. Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance. T Dogru A Sonmez I Tasci E Bozoglu MI Yilmaz H Genc G Erdem M Gok N Bingol S Kilic T Ozgurtas S Bingol, Diabetes Res Clin Pract 2007 76 1 24 29 10.1016/j.diabres.2006.07.031 16956691 (Pubitemid 46240362)
28. Plasma visfatin concentrations in subjects with type 1 diabetes mellitus. F Toruner AE Altinova N Bukan E Arslan E Akbay R Ersoy M Arslan, Horm Res 2009 72 1 33 37 10.1159/000224338 19571557
29. Visfatin is an adipokine, but it is not regulated by thiazolidinediones. A Hammarstedt J Pihlajamaki V Rotter Sopasakis S Gogg PA Jansson M Laakso U Smith, J Clin Endocrinol Metab 2006 91 3 1181 1184 10.1210/jc.2005-1395 16394088 (Pubitemid 43357799)
30. Free fatty acids normalize a rosiglitazone-induced visfatin release. DG Haider F Mittermayer G Schaller M Artwohl SM Baumgartner-Parzer G Prager M Roden M Wolzt, Am J Physiol Endocrinol Metab 2006 291 5 885 90 10.1152/ajpendo.00109. 2006 16735449
31. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. TB Dahl A Yndestad M Skjelland E Oie A Dahl A Michelsen JK Damas SH Tunheim T Ueland C Smith et al. Circulation 2007 115 8 972 980 10.1161/CIRCULATIONAHA.106.665893 17283255 (Pubitemid 46328290)
32. Extracellular PBEF/NAMPT/visfatin activates pro-inflammatory signalling in human vascular smooth muscle cells through nicotinamide phosphoribosyltransferase activity. T Romacho V Azcutia M Vazquez-Bella N Matesanz E Cercas J Nevado R Carraro L Rodriguez-Manas CF Sanchez-Ferrer C Peiro, Diabetologia 2009 19727662
33. Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes (ACS) in humans. SW Liu SB Qiao JS Yuan DQ Liu, Clin Endocrinol (Oxf) 2009 71 2 202 207 10.1111/j.1365-2265.2008.03453.x 19178507
34. Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis. M Zhong HW Tan HP Gong SF Wang Y Zhang W Zhang, Clin Endocrinol (Oxf) 2008 69 6 878 884 10.1111/j.1365-2265.2008.03248.x 18363885
35. Elevated visfatin/pre-B-cell colony-enhancing factor plasma concentration in ischemic stroke. LF Lu SS Yang CP Wang WC Hung TH Yu CA Chiu FM Chung SJ Shin YJ Lee, J Stroke Cerebrovasc Dis 2009 18 5 354 9 10.1016/j. jstrokecerebrovasdis.2009.01.003 19717018
36. The novel adipocytokine visfatin exerts direct cardioprotective effects. SY Lim SM Davidson AJ Paramanathan CC Smith DM Yellon DJ Hausenloy, J Cell Mol Med 2008 12 4 1395 1403 10.1111/j.1582-4934.2008.00332.x 18400051
37. Genetic variation in the visfatin gene (PBEF1) and its relation to glucose metabolism and fat-depot-specific messenger ribonucleic acid expression in humans. Y Bottcher D Teupser B Enigk J Berndt N Kloting MR Schon J Thiery M Bluher M Stumvoll P Kovacs, J Clin Endocrinol Metab 2006 91 7 2725 2731 10.1210/jc.2006-0149 16636125 (Pubitemid 44024644)
38. Common polymorphisms in the promoter of the visfatin gene (PBEF1) influence plasma insulin levels in a French-Canadian population. SD Bailey JC Loredo-Osti P Lepage J Faith J Fontaine KM Desbiens TJ Hudson C Bouchard D Gaudet L Perusse et al. Diabetes 2006 55 10 2896 2902 10.2337/db06-0189 17003359 (Pubitemid 44923693)
39. A visfatin promoter polymorphism is associated with low-grade inflammation and type 2 diabetes. YY Zhang L Gottardo R Thompson C Powers D Nolan J Duffy MC Marescotti A Avogaro A Doria, Obesity (Silver Spring) 2006 14 12 2119 2126 10.1038/oby.2006.247 17189536 (Pubitemid 46121965)
40. Effects of genetic variation in the visfatin gene (PBEF1) on obesity, glucose metabolism, and blood pressure in children. A Korner Y Bottcher B Enigk W Kiess M Stumvoll P Kovacs, Metabolism 2007 56 6 772 777 10.1016/j.metabol. 2007.01.009 17512309 (Pubitemid 46734084)
41. A rare variant in the visfatin gene (NAMPT/PBEF1) is associated with protection from obesity. AI Blakemore D Meyre J Delplanque V Vatin C Lecoeur M Marre J Tichet B Balkau P Froguel AJ Walley, Obesity (Silver Spring) 2009 17 8 1549 1553 10.1038/oby.2009.75 19300429
42. Genetic variant in visfatin gene promoter is associated with decreased risk of coronary artery disease in a Chinese population. JJ Yan NP Tang JJ Tang EZ Jia MW Wang QM Wang J Zhu ZJ Yang LS Wang J Huang, Clin Chim Acta 2009 doi:10.1016/j.cca.2009.09.033 19804767
43. The -1535 promoter variant of the visfatin gene is associated with serum triglyceride and HDL-cholesterol levels in Japanese subjects. A Tokunaga A Miura Y Okauchi K Segawa A Fukuhara K Okita M Takahashi T Funahashi J Miyagawa I Shimomura K Yamagata, Endocr J 2008 55 1 205 212 10.1507/endocrj.K07E-039 18270432 (Pubitemid 351520199)